|
|
| Author |
Message |
jackoozzi
specialist
|
| Joined: 10 Feb 2005 |
| Posts: 135 |
| Location: Australia |
39384.40 Points
|
|
|
phenylpropanolamine from benzaldehyde
Tue Mar 22, 2005 5:53 am |
|
|
I cut this out of a post at wd and was wondering if anyone has done this or has any more information
Uncle Fester says somewhere in SOMM that PPA can be made from benzaldehyde and alanine simply by heating the two together until CO2 evolution ceases. Hmmm. Cinnamon oil -> benzaldehyde, benzaldehyde -> PPA, PPA -> 4-MAR. OTC, and so simple that even pill-cooks might be able to do it. Is this the Next Big Drug Problem just waiting to happen?
--------------------------------------------------------------------------------
Country: | Posts: 7
Astrum
New Dreamer
Posted - Mar 21 2005 : 3:27:22 PM
--------------------------------------------------------------------------------
Alright, I did a little digging on making phenylpropanolamine from benzaldehyde and alanine. It's known as the Akabori-Momotani reaction. It's the aldol condensation of amino acids with aromatic aldehydes to give amino alcohols.
So the reaction we're looking at is:
C3H7NO2 + C7H6O -> CO2 + C9H13NO |
|
| Back to top |
|
 |
jackoozzi
specialist
|
| Joined: 10 Feb 2005 |
| Posts: 135 |
| Location: Australia |
39384.40 Points
|
|
|
Tue Mar 22, 2005 6:45 am |
|
|
And just witch isomer of alanine would you need there seems to be a few including
d alanine
l alanine
dl alanine
b alanine |
|
| Back to top |
|
 |
Astrum
|
| Joined: 19 Feb 2005 |
| Posts: 15 |
|
405.92 Points
|
|
|
Tue Mar 22, 2005 8:07 am |
|
|
Here's the diagram:
 |
|
| Back to top |
|
 |
CherrieBaby
chouchou
|
| Joined: 01 Mar 2005 |
| Posts: 67 |
|
3070.02 Points
|
|
|
Tue Mar 22, 2005 11:35 am |
|
|
The references (from the 13th Merck) are:
E. Takagi et al., J. Pharm. Soc. Japan 71, 648 (1951); 72, 812 (1952);
A. Lawson, H. V. Morley, J. Chem. Soc. 1955, 1695;
A. Lawson, ibid. 1956, 307;
K. Dose, Ber. 90, 1251 (1957);
H. V. Belikov et al., Izv. Akad. Nauk SSSR, Ser. Khim. 1969, 2336. |
|
| Back to top |
|
 |
jackoozzi
specialist
|
| Joined: 10 Feb 2005 |
| Posts: 135 |
| Location: Australia |
39384.40 Points
|
|
|
Wed Mar 23, 2005 12:24 am |
|
|
Here is a pic prom the merck references
 |
|
| Back to top |
|
 |
|
|
|
Amino acids
Wed Mar 23, 2005 1:12 pm |
|
|
I cautiously assume this is why L- alanine can be used, since it becomes racemic(dl-alanine) in situ,
This is good reading, the akabori, has quite a destiny,
Abstract of JP11322684
PROBLEM TO BE SOLVED: To improve the isomerization process, in other words, racemization and epimerization for optically active amino acids, typically alanine, &alpha - aminobutanoic acid, valine, leucine, isoleucine, phenylalanine, tryptophane and methionine, in the presence of a lower fatty acid and an aldehyde and provide an high-efficiency isomerization process for amino acids with lowered energy consumption and easy recycle of the lower fatty acid and aldehyde as the isomerization catalyst. SOLUTION: An optically active amino acid is dispersed in an inert solvent that substantially does not dissolve amino acids, preferably an aromatic hydrocarbon such as benzene, toluene, xylene or halogenated benzene. A lower fatty acid, preferably a 1-5C saturated fatty acid as acetic acid, propionic acid or butanoic acid and an aliphatic aldehyde or an aromatic aldehyde, preferably an aromatic aldehyde such as benzaldehyde or salicylaldehyde are allowed to act on the dispersion to effect the isomerization. The mixture of the optical isomers of the crystallized amino acid separating from the solvent are collected by the solid-liquid phase separation.
Abstract of JP57123150
PURPOSE:The racemization of an optically active aminoacid is effected in the presence of a lower fatty acid and an aromatic aldehyde to give the racemi aminoacid in high yield through one step and this process is applicable to a variety of aminoacids and the racemization rate is high. CONSTITUTION:An optically active aminoacid such as alanine, arginine, asparaginic acid or proline is racemized in the presence of a saturated fatty acid of 1-3 carbon atoms and an aromatic aldehyde such as benzaldehyde which may be a substituent such as hydroxyl, nitro, amino, methoxy or the like wherein the amount of the aldehyde is about 0.001-0.3mol and the lower fatty acid is more than 10 (V/V)% based on the optically active aminoacid.
Very interesting reading,
syn |
|
| Back to top |
|
 |
IndoleAmine
Dreamreader Deluxe
|
| Joined: 09 Feb 2005 |
| Posts: 681 |
| Location: Bahamas |
18717.10 Points
|
|
|
Wed Mar 23, 2005 8:11 pm |
|
|
Since
a) 1-phenylpropan-1-ol-2-amine (PPA) used in nasal decongestants (and cold medications) is the racemic d,l-ppa.hcl (no brand names; but there are MANY! )
b) this racemic PPA.HCl can be used to produce 4-MAR, like described in https://synthetikal.com/synthforum/viewtopic.php?t=127 ,
..I would assume that the racemic d,l-alanine OR the optically pure d-alanine are the correct ones to use in the akabori-momotani rxn - no?
But since alanine is isomerized/racemized easily by refluxing with GAA/BzCHO in toluene according to the above japanese patent (good find!), this is just of theoretical interest I think.
i_a |
|
| Back to top |
|
 |
IndoleAmine
Dreamreader Deluxe
|
| Joined: 09 Feb 2005 |
| Posts: 681 |
| Location: Bahamas |
18717.10 Points
|
|
|
| Back to top |
|
 |
Astrum
|
| Joined: 19 Feb 2005 |
| Posts: 15 |
|
405.92 Points
|
|
|
Thu Mar 24, 2005 9:16 am |
|
|
| Quote: |
|
a) 1-phenylpropan-1-ol-2-amine (PPA) used in nasal decongestants (and cold medications) is the racemic d,l-ppa.hcl (no brand names; but there are MANY! Wink )
|
It used to be used as a nasal decongestant but has since been banned in the USA. So there's no hope in finding it in pills around here.
I was under the impression that that the trans(4S,5S) stereoisomer was more active than the cis(4S,5R/4R,5S) stereoisomers. In which case l-alanine or d,l-alanine would be preferred. But I could be wrong, I'm dead tired right now . I'll look into it in the morning. |
|
| Back to top |
|
 |
IndoleAmine
Dreamreader Deluxe
|
| Joined: 09 Feb 2005 |
| Posts: 681 |
| Location: Bahamas |
18717.10 Points
|
|
|
Thu Mar 24, 2005 8:11 pm |
|
|
No, the d,l-cis-isomer of 4-MAR is the controlled CNS stimulant (according to merck) - but I am tempted to say that it doesn't matter as long as you use either d-, l- or racemic alanine; since PPA occurs just in one configuration, so you will end up with PPA no matter which isomer of alanine you use (at least ChemDraw 8.0 was not able to resolve the above "PPA" structure into optical isomers, so I would like to say there are no isomers in this case... then again I know nothing about stereochemistry and optical rotation.....)
(BTW in fact according to IUPAC "phenylpropanolamine" is a different compound and a secondary amine and the correct name is "1-phenylpropan-1-ol-2-amine"; but you all know what is meant with "PPA", right? )
And I'm dead sure that with d,l-alanine, you will get at least 50% of the given possible yield for the Akabori (and you can racemize all stereoisomers of ala very easily, see above).....
(very tired too, see y'all tomorrow...)
i_a |
|
| Back to top |
|
 |
|
|
|
isomers
Fri Mar 25, 2005 7:04 am |
|
|
I believe both isomers of 4-mar are active,
As the L-alanine would be racemerized to DL-alanine in situ,
Wouldn't this them mean you would have then dl-PPA,
But then what happens to L-PPA in the KOCN,
What happens when L-alanine insitu becomes DL-alanine,
does the dl-alanie, keep getting processed until it all D-alanine, or D-PPA?
IS there only one optical molecular configuration for PPA?
SO accoring to the patents,
If you wanted all d-alanine, you would have to separate out D-isomer, and reprocess, a few times the remaing L-alanine?
What process to we have for separation of stereo isomers?
Tartaric acid?
I don't think it's of too much concern,
As long as you are happy with a racemic mix,
Which Is probably a good mix
syn |
|
| Back to top |
|
 |
64bandil
Busy Bee
|
| Joined: 22 Mar 2005 |
| Posts: 35 |
|
1508.72 Points
|
|
|
Fri Mar 25, 2005 2:53 pm |
|
|
The cyanate route with norephedrine gives the trans isomer, whereas norephedrine with cyanogenbromide yields cis. norpseudoephedrine with CNBr gives trans and norpseudoephedrine with cyanogen bromide yields a crappy amide, thats completely inactive... phew! [edit: whops, i meant to say "norpseudoephedrine with cyanate yields a crappy amide, thats completely inactive
One of the trans isomers is actually the most potent one. But the less postent trans isomer, is the least potent of all the possible isomers... The potency list goes something like this:
trans-4-mar (isomer 1)
cis-4-mar(isomer 1)
cis-4-mar(isomer 2)
trans-4-mar(isomer 2)
So all in all they are pretty equipotent with respect to amount. 40 mg´s of either cis og trans will get me flying pretty high... Dont think I could tell them appart...
Regards
Bandil
Last edited by 64bandil on Sat Mar 26, 2005 2:22 pm; edited 1 time in total |
|
| Back to top |
|
 |
IndoleAmine
Dreamreader Deluxe
|
| Joined: 09 Feb 2005 |
| Posts: 681 |
| Location: Bahamas |
18717.10 Points
|
|
|
Fri Mar 25, 2005 7:52 pm |
|
|
Nice. So stereochemistry is not much of a concern in the PPA->4MAR step, I would say - right?
And my understanding is that the akabori-momotani gives only 1-phenylpropan-1-ol-2-amine (PPA), regardless which d, l or racemic stereomer of alanine you use, although it is possible that only one optical isomer will give 100% conversion - but since alanine is dirt cheap, it really shoudln't matter, since there is no "wrong" compound produced that could present a waste of aldehyde...
I think I will just try, visit my local pharmacy right after easter and tell'em I need a LOT of alanine, all isomers they have in stock (maybe I will have a serious nutrition disequilibrium, have a little sister with apoor ill rabbit, or wanna become a 200pound muscle monster by ingesting amino acids or something like that, what do you think?), and try and decarboxylate them with some BzCHO - maybe one ala isomer will give nearly double yields compared to the others, or maybe even 2x as much as the racemic and one wont work at all - we'll see....
(any stereochemistry expert wanna comment?)
i_a |
|
| Back to top |
|
 |
|
|
|
that would be good
Sat Mar 26, 2005 7:31 am |
|
|
It would be nice to see a bit of real world experimentation on this alanine species,
L-alanine comes in the HCL salt, i believe?
As i have sometimes noticed on the packaging,
syn |
|
| Back to top |
|
 |
Astrum
|
| Joined: 19 Feb 2005 |
| Posts: 15 |
|
405.92 Points
|
|
|
Sat Mar 26, 2005 4:27 pm |
|
|
| Quote: |
|
Like other phenylisopropylamine derivatives, 4-methylaminorex is a central stimulant. The cis isomer of 4-methylaminorex ("U4Euh"; "ICE") has appeared on the clandestine market as a novel designer drug and was recently classified as a Schedule I substance. In the present investigation, the stimulus properties of racemic cis, racemic trans, and all four individual optical isomers of 4-methylaminorex were examined in rats trained to discriminate 1 mg/kg of S(+)amphetamine sulfate from saline. The S(+)amphetamine stimulus generalized to all of the agents investigated and the relative potencies of the optical isomers (followed by ED50 values) were as follows:trans(4S,5S) (0.25 mg/kg) > cis(4S,5R) (1.2 mg/kg) = cis(4R,5S) (1.5 mg/kg) > trans(4R, 5R). The trans(4R,5R) isomer did not completely substitute for S(+)amphetamine unless a longer (i.e., 60-min) presession injection interval was used, suggesting that it has a longer duration of onset that the other isomers of 4-methylaminorex. The results, which are consistent with established structure-activity relationships, suggest that the trans(4S,5S) isomer (which has not been scheduled) is similar in potency to (+)amphetamine (ED50=0.4 mg/kg) and is more potent than either of the cis isomers.
|
Stimulus properties of a new designer drug: 4-methylaminorex ("U4Euh")
I'm well aware that d,l-cis-4-MAR is the scheduled one. In fact all four stereoisomers of 4-MAR are active making this somewhat of a trivial point. However, I was correct in saying that the trans(4S,5S) stereoisomer was the most potent of the four.
Phenylpropanolamine (1-phenylpropan-1-ol-2-amine) has four stereoisomers; l-norephedrine, d-norephedrine, l-norpseudoephedrine, and d-norpseudoephedrine. Theoretically which enantiomer of alanine you use will determine which stereoisomer of PPA you get as described by this:
The trans diastereomer is d,l-norephedrine where as the cis diastereomer is d,l-norpseudoephedrine. So basically l-alanine should condense with benzaldehyde to give you the trans(1S,2S) or cis(1S,2R) stereoisomers of PPA and likewise d-alanine should condense with benzaldehyde to give you the trans(1R,2R) or cis(1R,2S) stereoisomers. If however, d-alanine or l-alanine are in fact isomerized in situ in this reaction (to equilibrium I assume) then you should get a mix of all four stereoisomers. In which case what you want really depends on the type of reaction you're going to perform (cyanogen bromide or potassium cyanate).
So if you're bold enough to work with cyanogen bromide you can use any or all of the four stereoisomers of PPA that can be produced. If you're using potassium cyanate you need to isolate only the trans diastereomer, either enantiomer or both will work. I'll look into this more when I've had some sleep; but assuming minimal isomerization of the alanine enantiomer being used in conjunction with the potassium cyanate route, one enantiomer of alanine will lead to the weakest of the four stereoisomers while the other will lead to the strongest. So until someone can figure out which enantiomer of alanine leads to trans(4R,5R)-4-MAR I would suggest using d,l-alanine. If the cis diastereomer is used with potassium cyanate it will make trans-4-methyl-5-phenyl-oxazolid-2-one which can be catalytically hydrogenated to (S)-amphetamine if so desired.
That being said I haven't slept in 24 hours. So if anything doesn't make sense or I've made an error somewhere (which I surely have), please point it out to me and I'll correct it in the morning. |
|
| Back to top |
|
 |
|
|
|
Powered by phpBB 2.0.11 © 2001, 2002 phpBB Group
Igloo Theme Version 1.0 :: Created By: Andrew Charron
|